

NCT Number	Status	Conditions	Phase	Interventions	Combinations	Start Date	Location
NCT03929029	Not yet recruiting	Melanoma	Phase 1	Peptide vaccine	Drug: Nivolumab; Biological: NeoVax plus Montanide; Drug: Ipilimumab	6/30/2020	United States
NCT04024878	Not yet recruiting	Ovarian Cancer	Phase 1	Neoantigen vaccine	Drug: Nivolumab	6/1/2020	United States
NCT03219450	Not yet recruiting	Lymphocytic Leukemia	Phase 1	Peptide vaccine	Drug: Cyclophosphamide	5/1/2020	United States
NCT03598816	Not yet recruiting	Renal Cell Carcinoma	Phase 2	DNA Vaccine	Drug: Durvalumab; Drug: Tremelimumab	4/30/2020	United States
NCT04015700	Not yet recruiting	Glioblastoma	Phase 1	DNA vaccine	Plasmid encoded IL-12	3/31/2020	United States
NCT03988283	Not yet recruiting	Pediatric Recurrent Brain Tumor	Phase 1	DNA vaccine	None	3/31/2020	United States
NCT04251117	Not yet recruiting	HCC	Phase 1, Phase 2	DNA vaccine	Biological: GNOSPV02 Biological:INO-9012 Drug:Pembrolizumab	3/1/2020	United States, New Zealand
NCT04266730	Not yet recruiting	Lung Cancer; Squamous Cell Carcinoma of Head and Neck	Phase 1	Peptide vaccine	Biological: PANDA-VAC	2/28/2020	United States
NCT03068832	Not yet recruiting	Pediatric Brain Tumor	Phase 1	Peptide vaccine	Drug: Poly ICLC	2/28/2020	United States
NCT03956056	Not yet recruiting	Pancreas Cancer	Phase 1	Peptide vaccine	Adjuvant chemotherapy	1/31/2020	United States
NCT04087252	Recruiting	Cancer	Phase 1	Peptide vaccine	None	9/2/2019	China
NCT04072900	Not yet recruiting	Melanoma (Skin)	Phase 1	Peptide vaccine	Drug: Anti-PD-1; Drug: rhGM-CSF; Drug: Imiquimod 5% Topical Cream	9/1/2019	China
NCT03361852	Not yet recruiting	Follicular Lymphoma	Phase 1	Neoantigen vaccine	Drug: Rituximab	9/1/2019	United States
NCT04105582	Recruiting	Breast Cancer; Triple Negative Breast Cancer	Phase 1	Neoantigen pulsed Dendritic cell	None	8/1/2019	Colombia
NCT03953235	Recruiting	Non Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Solid Tumor	Phase 1, Phase 2	Neoantigen vaccine	Biological: GRTC903 Biological: GRTR904 Biological: nivolumab Biological: ipilimumab	7/18/2019	United States
NCT03970382	Recruiting	Solid Tumor	Phase 1	NeoTCR-P1 adoptive cell therapy	Biological: nivolumab	7/3/2019	United States
NCT03359239	Recruiting	Urothelial/Bladder Cancer, Nos	Phase 1	Peptide vaccine	Drug: Atezolizumab; Biological: PGV001; Drug: Poly ICLC; Drug: Normal saline	5/8/2019	United States

NCT Number	Status	Conditions	Phase	Interventions	Combinations	Start Date	Location
NCT03908671	Not yet recruiting	Esophageal Cancer; Non Small Cell Lung Cancer	Not Applicable	mRNA Vaccine	Biological:Personalized mRNA Tumor Vaccine	5/1/2019	Unknown
NCT03871205	Not yet recruiting	Carcinoma, Lung cancer	Phase 1	DC vaccine	None	4/1/2019	China
NCT03870113	Not yet recruiting	Cervical Intraepithelial Neoplasia	Phase 1	DC vaccine	None	4/1/2019	China
NCT03914768	Enrolling by invitation	Diffuse Intrinsic Pontine Glioma or Glioblastoma	Phase 1	DC vaccine	None	3/31/2019	China
NCT02950766	Recruiting	Kidney Cancer	Phase 1	Peptide vaccine	Drug: NeoVax; Drug: Ipilimumab	3/3/2019	United States
NCT03639714	Recruiting	Non Small Cell Lung Cancer; Colorectal Cancer; Gastroesophageal Adenocarcinoma; Urothelial Carcinoma	Phase 1, Phase 2	Peptide vaccine	Biological: GRTC901 Biological: GRTR902 Biological: nivolumab Biological: ipilimumab	2/13/2019	United States
NCT03715985	Recruiting	Malignant Melanoma, Metastatic ; Non Small Cell Lung Cancer, Metastatic Kidney Cancer, Metastatic	Phase 1	Peptide vaccine	Drug: EVAX-01-CAF09b	1/28/2019	Denmark
NCT03422094	Suspended	Glioblastoma	Phase 1	Peptide vaccine	Biological: NeoVax Biological: Nivolumab; Biological: Ipilimumab	10/31/2018	United States
NCT03674073	Recruiting	Hepatocellular Carcinoma; Liver cancer, adult	Phase 1	DC vaccine	Microwave Ablation	10/15/2018	China
NCT03532217	Recruiting	Metastatic Hormone-Sensitive Prostate Cancer	Phase 1	DNA vaccine	Biological: PROSTVAC-V Biological: PROSTVAC-F Drug: Nivolumab Drug: Ipilimumab	9/14/2018	United States
NCT03412877	Recruiting	Glioblastoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer; Gastrointestinal/Genitourinary Cancer	Phase 2	Individual Patient TCR- Transduced PBL	Drug: Cyclophosphamide Drug: Fludarabine Drug: Aldesleukin Drug: Pembrolizumab (KEYTRUDA)	9/6/2018	United States
NCT03468244	Recruiting	Advanced Esophageal Squamous Carcinoma; Gastric Adenocarcinoma; Pancreatic Adenocarcinoma; Colorectal Adenocarcinoma	Not Applicable	mRNA Vaccine	Biological: Personalized mRNA Tumor Vaccine	5/1/2018	China

NCT Number	Status	Conditions	Phase	Interventions	Combinations	Start Date	Location
NCT03199040	Recruiting	Triple Negative Breast Cancer	Phase 1	DNA vaccine	Drug: Durvalumab	4/20/2018	United States
NCT03558945	Recruiting	Pancreatic Tumor	Phase 1	Personalized neoantigen vaccine	None	4/2/2018	China
NCT03662815	Active, not recruiting	Advanced Malignant Solid Tumor	Phase 1	Neoantigen vaccine	Biological: iNeoVac-P01; Other: GM-CSF	2/7/2018	China
NCT03122106	Recruiting	Pancreas Cancer	Phase 1	DNA vaccine	Adjuvant chemotherapy	1/5/2018	United States
NCT03258359	Active, not recruiting	Myelodysplastic Syndromes	Phase 1	Adoptive Cellular Therapy	Biological: PACTN	1/1/2018	United States
NCT03645148	Recruiting	Pancreatic Cancer	Phase 1	Neoantigen vaccine	Biological: iNeoVac-P01; Other: GM-CSF	10/24/2017	China
NCT03171220	Recruiting	Advanced Malignant Solid Tumor	Phase 1, Phase 2	Neoantigen Reactive T Cells	Biological: SHR-1210 Drug: Fludarabine Drug: Cyclophosphamide Biological: Interleukin-2	6/1/2017	China
NCT02956551	Recruiting	Carcinoma, NonSmall-Cell Lung	Phase 1	DC vaccine	None	11/30/2016	China
NCT02632019	Unknown	Advanced Biliary Tract Malignant Tumor	Phase 1, Phase 2	Dendritic cell-precision T cell for neoantigen	Drug: Gemcitabine	9/1/2015	China
NCT02287428	Active, not recruiting	Glioblastoma	Phase 1	Peptide vaccine	Radiation Therapy; Drug: Pembrolizumab	11/1/2014	United States
NCT01970358	Active, not recruiting	Melanoma	Phase 1	Peptide vaccine	Biological: Poly ICLC	1/1/2014	United States
NCT01885702	Active, not recruiting	Colorectal Cancer	Phase 1, Phase 2	DC vaccine	None	10/1/2010	Netherlands

*Source: Data extracted on March 09, 2020 from clinicaltrials.gov

*Note: The data may be incomplete and missing some information. For more clinical trials and data, please refer to clinicaltrials.gov